Disc Medicine’s Bitopertin Shines, Science Talent Drain Sparks Policy Debate, Vedolizumab Clears UC Without Steroids, Doughnut Model Reveals Critical Links, and more...

Podcast: Science News Daily · brief.news

Opublikowano: 2026-10-20

(0:10): Disc Medicine's Bitopertin Shines in Phase 3 EPP Trial, Paving Way for FDA Submission (1:57): US Faces Science Talent Drain Amid Policy Shifts, Immigrant Contributions Highlighted (3:54): Vedolizumab Achieves Corticosteroid-Free Disease Clearance, Reduces UC Complications in Phase 4 VERDICT Trial (6:27): Breakthrough Study Links Topology to Critical Phenomena Using Doughnut Model (8:09): Japan's Leading Biobank Surpasses 250,000 Participants, Expands Global Research Access To subscribe visit https://www.brief.news. For more updates in your inbox each morning visit www.brief.news. Image credit: Shoreline Media Group